In last trading session, Lucid Diagnostics Inc (NASDAQ:LUCD) saw 0.53 million shares changing hands with its beta currently measuring 1.52. Company’s recent per share price level of $1.46 trading at -$0.03 or -2.01% at ring of the bell on the day assigns it a market valuation of $86.64M. That closing price of LUCD’s stock is at a discount of -11.64% from its 52-week high price of $1.63 and is indicating a premium of 56.85% from its 52-week low price of $0.63.
For Lucid Diagnostics Inc (LUCD), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 3 analysts covering the stock, 1 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 2 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.15 in the current quarter.
Lucid Diagnostics Inc (NASDAQ:LUCD) trade information
Upright in the red during last session for losing -2.01%, in the last five days LUCD remained trading in the green while hitting it’s week-highest on Wednesday, 02/19/25 when the stock touched $1.46 price level, adding 10.59% to its value on the day. Lucid Diagnostics Inc’s shares saw a change of 78.33% in year-to-date performance and have moved 7.35% in past 5-day. Lucid Diagnostics Inc (NASDAQ:LUCD) showed a performance of 77.03% in past 30-days.
Wall Street analysts have assigned a consensus price target of 2.5 to the stock, which implies a rise of 41.6% to its current value. Analysts have been projecting 2.5 as a low price target for the stock while placing it at a high target of 2.5. It follows that stock’s current price would drop -71.23% in reaching the projected high whereas dropping to the targeted low would mean a loss of -71.23% for stock’s current value.
Lucid Diagnostics Inc (LUCD) estimates and forecasts
This year revenue growth is estimated to rise 88.04% from the last financial year’s standing.
6 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 1.42M for the same. And 5 analysts are in estimates of company making revenue of 1.61M in the next quarter. Company posted 1.04M and 1M of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -110.66% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 84.60% while estimates for its earnings growth in next 5 years are of 58.74%.
Lucid Diagnostics Inc (NASDAQ:LUCD)’s Major holders
LUMINUS MANAGEMENT LLC is the top institutional holder at LUCD for having 0.73 million shares of worth $0.6 million. And as of 2024-06-30, it was holding 1.6124 of the company’s outstanding shares.
The second largest institutional holder is VANGUARD GROUP INC, which was holding about 0.56 million shares on 2024-06-30. The number of shares represents firm’s hold over 1.2461 of outstanding shares, having a total worth of $0.46 million.
On the other hand, Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund are the top two Mutual Funds which own company’s shares. As of Sep 30, 2024 , the former fund manager was holding 366.92 shares of worth $0.54 million or 0.62% of the total outstanding shares. The later fund manager was in possession of 193.99 shares on Sep 30, 2024 , making its stake of worth around $0.28 million in the company or a holder of 0.33% of company’s stock.
